In the past 5 years:

• 160+Clinical Trials
• 35+Indications
• 2,100+Sites
• 11,500+Patients

In-Depth Trending Oncology Experience

From recruiting patients with specific biomarkers and genetic characteristics to navigating complex logistics and timing with individualized therapies and addressing evolving trial designs—effectively managing oncology clinical trials can be challenging.

We understand oncology clinical trials.

In the past 5 years alone, Synteract has managed 160+ clinical oncology trials, with the greatest percentage of those in complex, challenging areas such as pathway-targeted therapies, chemotherapy, and immunotherapy, as well as cell-based therapies and gene therapies.

Our 30-year, in-depth oncology trial knowledge spans the entire clinical process, from design and execution of proof-of-concept trials to submissions and regulatory approval.

• We were one of the first CROs that began working in the innovative immunotherapy clinical development area over 10 years ago.
• We have first-hand experience and specialized expertise in precision medicine trials matched to specific patient biomarkers and personalized treatments customized to the individual.

Every project is unique, and we treat it accordingly. With greater than 85 percent of our project management team having oncology experience, our caring, highly skilled experts are personally driven to develop better therapies for patients.

In the highly-dynamic and evolving precision medicine cancer research landscape, we bring our longstanding oncology acumen to bear. We have performed more than 500 Phase I-IV oncology projects over our history, including hematological malignancies and other cancer types. We have developed a particular depth of experience in early phase oncology research for drugs designed to treat blood, breast, lung, gastrointestinal, skin, and numerous other cancers. The strong relationships we’ve developed with oncology investigative sites support your mission to advance treatments in this critical area of research. Learn about our experience navigating rare cancer and complex immunotherapy clinical trials.